Compare MDGL & CHRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDGL | CHRD |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | 531 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 5.3B |
| IPO Year | N/A | 2010 |
| Metric | MDGL | CHRD |
|---|---|---|
| Price | $537.20 | $90.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $553.08 | $133.36 |
| AVG Volume (30 Days) | 300.3K | ★ 614.2K |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 5.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.96 |
| Revenue | $740,640,000.00 | ★ $4,850,258,000.00 |
| Revenue This Year | $436.04 | N/A |
| Revenue Next Year | $53.17 | N/A |
| P/E Ratio | ★ N/A | $31.71 |
| Revenue Growth | ★ 864.21 | 9.04 |
| 52 Week Low | $265.00 | $79.83 |
| 52 Week High | $605.00 | $129.32 |
| Indicator | MDGL | CHRD |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 42.01 |
| Support Level | $544.24 | $90.52 |
| Resistance Level | $561.00 | $101.13 |
| Average True Range (ATR) | 19.91 | 2.72 |
| MACD | -8.26 | -0.63 |
| Stochastic Oscillator | 9.39 | 1.30 |
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Chord Energy Corp is an independent exploration and production company. The company acquires, exploits, develops, and explores crude oil, natural gas, and natural gas liquids in the Williston Basin.